HCM - Hutchison China MediTech GAAP EPADS of -$0.96 revenue of $202.05M
- Hutchison China MediTech press release ( NASDAQ: HCM ): 1H GAAP EPADS of -$0.96.
- Revenue of $202.05M (+28.4% Y/Y).
- Oncology/Immunology consolidated revenues for FY2022 to be in the range of $160M to $190M.
- “We have driven revenue growth in our innovative portfolio of marketed drugs. With ELUNATE ® for CRC 3 and following last year’s successful launches of ORPATHYS ® for MET-driven NSCLC and SULANDA ® for epNETs 4 and pNETs 5 , this will be the first full year of product sales from three novel, in-house discovered oncology products in China, with strong sales momentum. We have also significantly expanded our in-house commercial team to drive growth. On top of this, in June we announced that TAZVERIK ® was approved for use in the Hainan Pilot Zone, bringing the clinical benefits of a fourth product to patients in China.”
For further details see:
Hutchison China MediTech GAAP EPADS of -$0.96, revenue of $202.05M